Association between Ophthalmic Timolol and Hospitalisation for Bradycardia
Introduction. Ophthalmic timolol, a topical nonselective beta-blocker, has the potential to be absorbed systemically which may cause adverse cardiovascular effects. This study was conducted to determine whether initiation of ophthalmic timolol was associated with an increased risk of hospitalisation...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2015/567387 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551655199997952 |
|---|---|
| author | Nicole L. Pratt Emmae N. Ramsay Lisa M. Kalisch Ellett Tuan A. Nguyen Elizabeth E. Roughead |
| author_facet | Nicole L. Pratt Emmae N. Ramsay Lisa M. Kalisch Ellett Tuan A. Nguyen Elizabeth E. Roughead |
| author_sort | Nicole L. Pratt |
| collection | DOAJ |
| description | Introduction. Ophthalmic timolol, a topical nonselective beta-blocker, has the potential to be absorbed systemically which may cause adverse cardiovascular effects. This study was conducted to determine whether initiation of ophthalmic timolol was associated with an increased risk of hospitalisation for bradycardia. Materials and Methods. A self-controlled case-series study was undertaken in patients who were hospitalised for bradycardia and were exposed to timolol. Person-time after timolol initiation was partitioned into risk periods: 1–30 days, 31–180 days, and >180 days. A 30-day risk period prior to initiating timolol was also included. All remaining time was considered unexposed. Results. There were 6,373 patients with at least one hospitalisation for bradycardia during the study period; 267 were exposed to timolol. Risk of bradycardia was significantly increased in the 31–180 days after timolol initiation (incidence rate ratio (IRR) = 1.93; 95% confidence interval (CI) 1.00–1.87). No increased risk was observed in the first 30 days or beyond 180 days of continuous exposure (IRR = 1.40; 95% CI 0.87–2.26 and IRR = 1.21; 95% CI 0.64–2.31, resp.). Conclusion. Bradycardia is a potential adverse event following timolol initiation. Practitioners should consider patient history before choosing a glaucoma regime and closely monitor patients after treatment initiation with topical nonselective beta-blocker eye drops. |
| format | Article |
| id | doaj-art-28ab4cd7fda846cf961926f816c64652 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-28ab4cd7fda846cf961926f816c646522025-02-03T06:00:53ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/567387567387Association between Ophthalmic Timolol and Hospitalisation for BradycardiaNicole L. Pratt0Emmae N. Ramsay1Lisa M. Kalisch Ellett2Tuan A. Nguyen3Elizabeth E. Roughead4Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, AustraliaQuality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, AustraliaQuality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, AustraliaQuality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, AustraliaQuality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, AustraliaIntroduction. Ophthalmic timolol, a topical nonselective beta-blocker, has the potential to be absorbed systemically which may cause adverse cardiovascular effects. This study was conducted to determine whether initiation of ophthalmic timolol was associated with an increased risk of hospitalisation for bradycardia. Materials and Methods. A self-controlled case-series study was undertaken in patients who were hospitalised for bradycardia and were exposed to timolol. Person-time after timolol initiation was partitioned into risk periods: 1–30 days, 31–180 days, and >180 days. A 30-day risk period prior to initiating timolol was also included. All remaining time was considered unexposed. Results. There were 6,373 patients with at least one hospitalisation for bradycardia during the study period; 267 were exposed to timolol. Risk of bradycardia was significantly increased in the 31–180 days after timolol initiation (incidence rate ratio (IRR) = 1.93; 95% confidence interval (CI) 1.00–1.87). No increased risk was observed in the first 30 days or beyond 180 days of continuous exposure (IRR = 1.40; 95% CI 0.87–2.26 and IRR = 1.21; 95% CI 0.64–2.31, resp.). Conclusion. Bradycardia is a potential adverse event following timolol initiation. Practitioners should consider patient history before choosing a glaucoma regime and closely monitor patients after treatment initiation with topical nonselective beta-blocker eye drops.http://dx.doi.org/10.1155/2015/567387 |
| spellingShingle | Nicole L. Pratt Emmae N. Ramsay Lisa M. Kalisch Ellett Tuan A. Nguyen Elizabeth E. Roughead Association between Ophthalmic Timolol and Hospitalisation for Bradycardia Journal of Ophthalmology |
| title | Association between Ophthalmic Timolol and Hospitalisation for Bradycardia |
| title_full | Association between Ophthalmic Timolol and Hospitalisation for Bradycardia |
| title_fullStr | Association between Ophthalmic Timolol and Hospitalisation for Bradycardia |
| title_full_unstemmed | Association between Ophthalmic Timolol and Hospitalisation for Bradycardia |
| title_short | Association between Ophthalmic Timolol and Hospitalisation for Bradycardia |
| title_sort | association between ophthalmic timolol and hospitalisation for bradycardia |
| url | http://dx.doi.org/10.1155/2015/567387 |
| work_keys_str_mv | AT nicolelpratt associationbetweenophthalmictimololandhospitalisationforbradycardia AT emmaenramsay associationbetweenophthalmictimololandhospitalisationforbradycardia AT lisamkalischellett associationbetweenophthalmictimololandhospitalisationforbradycardia AT tuananguyen associationbetweenophthalmictimololandhospitalisationforbradycardia AT elizabetheroughead associationbetweenophthalmictimololandhospitalisationforbradycardia |